Durable Capital Partners LP Invests $122.91 Million in Option Care Health, Inc. $OPCH

Key Points

• Durable Capital Partners LP has invested approximately $122.91 million in Option Care Health, acquiring over 3.5 million shares, which represents 1.1% of their portfolio.
• Option Care Health reported a 15.4% year-over-year increase in revenue to $1.42 billion and earnings per share of $0.41, beating expectations.
• Analysts continue to have a positive outlook, with a consensus rating of "Moderate Buy" and an average price target of $35.75 for Option Care Health shares.

Durable Capital Partners LP acquired a new position in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,516,589 shares of the company's stock, valued at approximately $122,905,000. Option Care Health makes up approximately 1.1% of Durable Capital Partners LP's investment portfolio, making the stock its 29th largest position. Durable Capital Partners LP owned approximately 2.15% of Option Care Health at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of OPCH. Northwestern Mutual Wealth Management Co. boosted its holdings in Option Care Health by 1,492.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company's stock worth $31,000 after purchasing an additional 836 shares in the last quarter. Brooklyn Investment Group boosted its holdings in Option Care Health by 186.6% in the first quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock worth $42,000 after purchasing an additional 780 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in Option Care Health by 21.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock worth $43,000 after purchasing an additional 332 shares in the last quarter. Bessemer Group Inc. boosted its holdings in Option Care Health by 62.3% during the first quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock valued at $54,000 after acquiring an additional 599 shares during the period. Finally, Wealthquest Corp bought a new stake in Option Care Health during the first quarter valued at about $66,000. 98.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on OPCH. JMP Securities upped their price target on shares of Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a report on Thursday, July 31st. Barrington Research restated an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a report on Thursday, July 10th. Finally, Citigroup reissued an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Option Care Health has an average rating of "Moderate Buy" and an average price target of $35.75.

Option Care Health Stock Performance

Shares of OPCH traded up $0.49 on Wednesday, reaching $28.93. 1,900,211 shares of the stock traded hands, compared to its average volume of 1,717,588. The firm has a market cap of $4.70 billion, a price-to-earnings ratio of 23.14, a P/E/G ratio of 1.75 and a beta of 0.82. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.00. Option Care Health, Inc. has a 12 month low of $21.39 and a 12 month high of $35.53. The stock's 50-day moving average price is $29.42 and its 200-day moving average price is $31.59.

Option Care Health (NASDAQ:OPCH - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.01. The firm had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The business's revenue was up 15.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.30 earnings per share. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. Equities analysts forecast that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Insider Buying and Selling at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. bought 36,000 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were purchased at an average price of $27.15 per share, with a total value of $977,400.00. Following the completion of the purchase, the director owned 375,390 shares of the company's stock, valued at $10,191,838.50. This represents a 10.61% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Timothy P. Sullivan bought 20,000 shares of the business's stock in a transaction on Thursday, August 21st. The stock was bought at an average cost of $27.51 per share, for a total transaction of $550,200.00. Following the purchase, the director directly owned 49,229 shares of the company's stock, valued at approximately $1,354,289.79. This trade represents a 68.43% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.64% of the company's stock.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.